Gyre Therapeutics, Inc.
General ticker "GYRE" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $797.6M (TTM average)
Gyre Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -9.9%.
Estimated limits based on current volatility of 2.1%: low 8.19$, high 8.54$
Factors to consider:
- Total employees count: 5 as of 2024
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [7.72$, 16.67$]
- 2025-12-31 to 2026-12-31 estimated range: [6.71$, 14.63$]
Financial Metrics affecting the GYRE estimates:
- Positive: with PPE of 148.5 at the end of fiscal year the price was low
- Negative: Operating cash flow per share per price, % of -0.36 <= 0.06
- Positive: 7.67 < Operating profit margin, % of 15.28
- Negative: Investing cash flow per share per price, % of -1.97 <= -0.64
- Negative: Inventory ratio change, % of 1.95 > 0.79
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: 42.74 < Shareholder equity ratio, % of 50.49 <= 64.46
- Positive: Return on assets ratio (scaled to [-100,100]) of 12.49 > 6.13
Short-term GYRE quotes
Long-term GYRE plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $102.29MM | $113.45MM | $105.76MM |
| Operating Expenses | $93.09MM | $180.68MM | $89.59MM |
| Operating Income | $9.20MM | $-67.23MM | $16.16MM |
| Non-Operating Income | $0.21MM | $-9.73MM | $7.05MM |
| R&D Expense | $16.69MM | $13.78MM | $12.02MM |
| Income(Loss) | $9.41MM | $-76.97MM | $23.22MM |
| Taxes | $5.10MM | $8.52MM | $5.32MM |
| Profit(Loss)* | $2.30MM | $-92.93MM | $12.09MM |
| Stockholders Equity | $42.52MM | $-15.83MM | $63.32MM |
| Inventory | $6.12MM | $4.28MM | $6.34MM |
| Assets | $84.75MM | $116.54MM | $125.41MM |
| Operating Cash Flow | $10.68MM | $25.89MM | $-3.64MM |
| Capital expenditure | $5.00MM | $8.59MM | $3.13MM |
| Investing Cash Flow | $-13.81MM | $-19.76MM | $-19.88MM |
| Financing Cash Flow | $0.00MM | $2.50MM | $2.10MM |
| Earnings Per Share** | $0.03 | $-1.41 | $0.14 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.